Core Insights - Illumina has consistently beaten earnings estimates, with an average surprise of 8.85% over the last two quarters [1] - The company reported earnings of $1.19 per share for the last quarter, exceeding the Zacks Consensus Estimate of $1.02 per share by 16.67% [2] - Recent estimates for Illumina have been increasing, indicating positive sentiment among analysts [5] Earnings Performance - In the previous quarter, Illumina's earnings were $0.97 per share, surpassing the expected $0.96 per share, resulting in a surprise of 1.04% [2] - The Zacks Earnings ESP for Illumina is currently +1.72%, suggesting bullish sentiment regarding the company's earnings prospects [8] Predictive Metrics - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [6] - The Most Accurate Estimate, which is part of the Zacks Earnings ESP, reflects the latest analyst revisions and may provide a more accurate prediction than earlier consensus estimates [7]

Core Insights - Illumina, Inc. has launched BioInsight, a new business unit aimed at providing deeper biological insights to meet the growing demand from researchers and pharmaceutical companies for multiomic data interpretation [1][9] - Rami Mehio has been appointed as the senior vice president and general manager of BioInsight, joining Illumina's executive leadership team [2] - Following the announcement, Illumina's stock (ILMN) rose by 7.7% to close at $102.26, reflecting investor confidence in the company's innovative solutions and long-term growth potential [3] Company Developments - BioInsight will focus on supporting data generation through large national research initiatives, corporate partnerships, and federated data networks, expanding beyond traditional genomics to include advanced biological data types [6][10] - The new division aims to leverage multimodal data to help customers achieve faster and more meaningful results in drug discovery and disease diagnosis [7][10] - Illumina's current market capitalization stands at $15.72 billion, with an earnings yield of 4.3%, significantly outperforming the industry's -20.5% [4] Industry Context - The global multiomics market is projected to grow from $2.7 billion in 2024 to a compound annual growth rate (CAGR) of 15.3% by 2033, driven by advancements in omics technologies and increasing demand for single-cell multiomics [11] - Illumina's recent collaborations with global pharmaceutical companies aim to develop companion diagnostics focused on KRAS alterations, which are linked to cancer [12] Stock Performance - Over the past six months, Illumina's stock has increased by 33.8%, outperforming the industry average of 18.4% [13]

Core Insights - Illumina, Inc. (ILMN) is partnering with global pharmaceutical companies to develop companion diagnostics (CDx) based on the TruSight Oncology (TSO) Comprehensive genomic profiling test, focusing on KRAS alterations linked to cancer growth [1][10] Company Developments - The expansion of tumor-agnostic CDx claims demonstrates Illumina's commitment to enhancing patient access to precision oncology through standardized tests [2] - Illumina's TSO Comprehensive generates molecular tumor profiles to assist clinicians in matching patients with targeted therapies based on genetic mutations [3][10] - The development of CDx claims for KRAS will facilitate broader identification of patients who may benefit from targeted therapies, irrespective of tumor origin [6] Industry Context - The global CDx market was valued at $9.06 billion in 2024, with a projected compound annual growth rate of 10.5% through 2030, driven by the increasing prevalence of cancer and the demand for targeted therapies [7][8] - The integration of CDx into drug development pipelines by pharmaceutical companies is expected to enhance the success rate of novel therapeutics, further propelling market growth [8] Technological Advancements - Illumina introduced the Illumina Protein Prep, an assay that enhances next-generation sequencing (NGS)-based proteomics discovery, capable of measuring 9,500 unique human protein targets [9]

Illumina Inc. (NASDAQ:ILMN) ranks among the top NASDAQ stocks with low P/E ratios. On September 23, Illumina Inc. (NASDAQ:ILMN) announced that it would collaborate with several global pharmaceutical companies to create companion diagnostics (CDx) for KRAS biomarkers on its TruSight Oncology Comprehensive genomic profiling test. The collaborations are intended to increase tumor-agnostic CDx claims for KRAS mutations, which are known to result in uncontrolled cell growth that can lead to cancer. By identif ...

Core Insights - Illumina has launched BioInsight, a new business unit focused on developing data assets, software, and AI solutions to enhance life sciences research and drug development [1][3][4] - BioInsight aims to provide pharmaceutical companies with access to large omics datasets to facilitate target discovery and advance drug development [1][5] Business Focus - BioInsight will be led by Rami Mehio, who has extensive experience in software and informatics within Illumina [2] - The business will leverage Illumina's strengths in sequencing, data analysis, software, and AI to empower customers in identifying drug targets and understanding biological pathways [1][3] Technological Advancements - The reduction in sequencing costs and the rise of AI capabilities are transforming the generation of biological insights, enabling unprecedented scale in multiomic data generation [4][5] - BioInsight will support data generation through national research initiatives, corporate partnerships, and federated data networks, expanding beyond traditional genomics [6][8] AI and Tool Development - BioInsight is designed to harness multimodal data to create tools that help customers achieve meaningful results more quickly [7][8] - The focus includes developing software solutions for population-scale data analysis and providing secure data access for research and pharmaceutical partners [7][8]

Core Insights - The Precision Oncology market is experiencing significant growth, projected to have a CAGR of 8% from 2025 to 2030, with Tempus AI and Illumina as key players [2] Tempus AI - Tempus AI's oncology segment integrates genomic testing, liquid biopsy, and AI-driven diagnostics to personalize cancer treatment and enhance drug discovery [3] - The company has seen a 61.2% increase in share price over the past year, contrasting with Illumina's 25.2% decline [4] - Recent partnerships with AstraZeneca and Pathos AI aim to develop a multimodal foundation model in oncology, while collaboration with Verastem Oncology focuses on a companion diagnostic test for specific cancers [6] - Innovations include the introduction of xM, a liquid biopsy assay for monitoring treatment response, and the upcoming PurIST RNA-based test for pancreatic cancer classification [7] - Tempus has expanded its AI-enabled care pathway platform into breast cancer, addressing care gaps [8] - The company reported a significant operational improvement with an adjusted gross margin increase of 1649 basis points, despite rising costs [9] - Tempus raised its 2025 sales guidance to approximately $1.26 billion, indicating nearly 82% annual growth, and expects a positive adjusted EBITDA of $5 million in 2025 [10] Illumina - Illumina has established multiple pharmaceutical partnerships, including collaborations with Labcorp and Janssen to enhance genomic testing and develop a molecular residual disease assay [11] - The company is expanding its in vitro diagnostic portfolio through partnerships, such as with Pillar Biosciences for companion diagnostics [12] - Illumina's TruSight Oncology 500 assay continues to gain traction, with the launch of an upgraded version that streamlines genomic profiling [13] - Despite revenue declines, Illumina's non-GAAP gross margin improved to 69.4%, and the operating profit increased by approximately 4% year over year [14] - The company has adjusted its 2025 sales decline outlook to a range of 0.5-2.5% and projects non-GAAP diluted EPS of $4.45-$4.55 [15] Valuation and Estimates - Tempus AI is trading at a forward P/S ratio of 9.36, while Illumina's is at 3.34, indicating a more attractive valuation for Illumina [16] - The Zacks Consensus Estimate for Tempus's 2025 sales implies an 81.21% growth, while Illumina's estimates indicate a 2.5% decline [19] - Analysts expect positive earnings growth for Illumina, with stable earnings estimates over the past month [20] Investment Considerations - Both companies exhibit strong fundamentals, with Tempus focusing on growth through collaborations and next-gen diagnostics, while Illumina strengthens its oncology leadership and operational efficiency [22] - Despite Tempus's superior stock performance, Illumina's more attractive valuation may present a favorable investment opportunity [22]

Group 1 - Illumina's stock has dropped by 11% in a week due to increased competition from China's MGI Tech, which is gaining market share in DNA sequencing [2] - MGI Tech's global market presence remains strong despite a recent decline in international sales due to U.S. sanctions [2] - IQVIA presents stronger revenue growth at 5.3% compared to Illumina's decline of 4.8%, indicating a potentially better investment opportunity [3][6] Group 2 - Illumina offers solutions for genomic analysis and sequencing, serving research and clinical markets globally [4] - IQVIA provides advanced analytics and clinical research services, including cloud applications and project management for the life sciences sector [4] - IQVIA's revenue growth for the last 12 months is 3.6%, surpassing Illumina's -3.3%, and IQVIA's average margin is 13.7% compared to Illumina's 6.7% [6]

Illumina and pharma partners will develop companion diagnostics for historically important KRAS biomarker SAN DIEGO , Sept. 23, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN)Â will partner with multiple global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the TruSight™ Oncology (TSO) Comprehensive genomic profiling test. ...

Group 1: Brown Advisory Global Leaders Strategy Overview - Brown Advisory released its second-quarter 2025 investor letter for the Global Leaders Strategy, focusing on long-term performance through a concentrated portfolio of companies that address customer needs and yield good shareholder returns [1] - The strategy outperformed its benchmark during the quarter, primarily due to investment selection in Information Technology and Industrials [1] Group 2: Illumina, Inc. (NASDAQ:ILMN) Performance - Illumina, Inc. is highlighted as a key stock in the investor letter, with a one-month return of 3.10% and a 52-week loss of 21.02%, closing at $102.75 per share on September 19, 2025, with a market capitalization of $15.793 billion [2] - In the second quarter, Illumina generated approximately $1.06 billion in revenue, reaching the upper end of its guidance range, despite a 3% decline compared to Q2 2024 [4] Group 3: Investment Decisions Regarding Illumina, Inc. - Brown Advisory exited its position in Illumina in May due to a combination of regulatory changes, budget cuts from the National Institute of Health in the U.S., a complete import ban on sales into China, and increased competitive risks [3] - The number of hedge funds holding Illumina decreased from 60 to 54 in the second quarter, indicating a decline in popularity among institutional investors [4]

Core Insights - Alnylam Pharmaceuticals has joined the Alliance for Genomic Discovery (AGD), which aims to accelerate drug discovery through clinical genomic data [1][2][3] - The AGD dataset will enhance Alnylam's ability to identify new therapeutic targets for RNA interference (RNAi) therapeutics, which work by silencing disease-causing genes [4][5] - The AGD now includes nine members, with Alnylam being the latest addition, and plans to expand its dataset by sequencing an additional 31,250 whole genomes, building on an existing cohort of 250,000 [3][5] Company and Industry Developments - The AGD is led by Illumina and Nashville Biosciences, focusing on leveraging genomic data to drive innovation in therapeutics [2][3] - Alnylam's participation is expected to strengthen the AGD's clinical genomic database, which aims to provide diverse and representative data for drug discovery [5][6] - The alliance has already identified novel therapeutic targets, particularly in autoimmune and neurodegenerative diseases, demonstrating the dataset's value to its members [6][8] Technological Advancements - The AGD utilizes advanced sequencing and data analysis technologies, such as DRAGEN and Illumina Connected Analytics, to enhance the accuracy and speed of genomic insights [6][8] - The alliance plans to incorporate multiomic layers into its dataset, which will facilitate faster target discovery and therapy development [8] - The AGD dataset aims to link diverse genomic data with clinical phenotyping to ensure that discoveries benefit a wide range of populations [5][6]